Home/ Stocks/ KPRX

Kiora Pharmaceuticals, Inc. Common Stock

KPRX XNAS

$2.06 +0.02 (+0.98%) ▲ 15-min delayed

Open

$2.04

High

$2.16

Low

$2.04

Volume

22.6K

Market Cap

$7.50M

About Kiora Pharmaceuticals, Inc. Common Stock

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 12 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$26.8K	$0.01
Q2 2025	$0	$-2,152,459	$-0.54
Q1 2025	$0	$-2,192,980	$-0.52
FY 2024	$16.02M	$3.59M	$0.93

Related Market News

No specific coverage for KPRX yet. Check out our latest market news or earnings calendar.

Get KPRX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Kiora Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.